GRAND CANYON EDUCATION, INC. REPORTS THIRD QUARTER 2026 RESULTS

Grand Canyon Education reported Q3 2026 service revenue of $267.3 million, up 2.4% year over year, while GAAP diluted EPS rose to $1.67 from $0.58; adjusted diluted EPS was nearly flat at $1.77 versus $1.78, and adjusted EBITDA fell 3.2% to $73.5 million. University partner enrollments increased 5.2% to 145,270, but the company cited a $7.5 million revenue shift into Q4 from the academic calendar. GCE raised its existing repurchase authorization by $355.0 million to an aggregate $2.9 billion and reiterated full-year 2026 diluted EPS guidance of $9.81–$9.85.

Analysis

The headline GAAP rebound is a poor read-through to run-rate earnings: the prior-year quarter carried a large litigation charge, while adjusted EPS was essentially flat and adjusted EBITDA fell 3.2%. The more relevant signal is that enrollment growth is not converting cleanly into revenue or operating leverage. Online growth is arriving with lower net tuition mix, ground enrollment is contracting, and the reported 2.4% quarterly revenue gain is also clouded by the GCU contract change and a $7.5 million calendar shift into Q4. The Q4 outlook should therefore be judged on whether that deferred revenue actually lands—not treated as fresh acceleration.

The better structural offset is faster growth at off-campus nursing sites, where GCE says its economics per student are higher. If that mix continues to scale, it could cushion online pricing/mix pressure; verify site-level enrollment, retention, and contribution economics before underwriting it. Conversely, reliance on the largest university partner leaves LOPE exposed to contract, regulatory, and partner-level disruptions.

Capital returns flatter the per-share story but reduce flexibility: repurchases and capex exceeded operating cash generation over the first nine months, and liquidity fell materially. The expanded authorization is not a purchase commitment. Near term, the market may reward Q4 seasonality and buyback support; over 1–3 months, the call’s evidence on Q4 timing and marketing/counseling costs matters more. Over 6–18 months, enrollment quality, nursing-site economics, and partner concentration dominate. Contrarian read: avoid extrapolating the GAAP EPS surge; underlying results are mixed, not a clean reacceleration.

Key Decisions for Investors

• Do not chase LOPE on the GAAP EPS comparison alone. Treat the print as mixed and wait for the conference call and next guidance update to confirm whether the $7.5 million revenue timing shift is recovered in Q4.
• Keep exposure neutral pending confirmation of operating leverage. Upgrade the thesis only if revenue growth begins to outpace enrollment growth without further deterioration in adjusted EBITDA or adjusted margins; downgrade if online net tuition mix worsens or marketing and counseling costs continue to rise faster than revenue.
• Monitor repurchase pace against cash generation and liquidity. The authorization can support per-share results, but a sustained gap between buybacks/capex and operating cash flow would weaken that support; verify any revolving-credit use rather than assuming the authorization will be fully deployed.
• Falsifiers: Q4 revenue fails to reflect the disclosed timing shift; management cuts full-year guidance; off-campus nursing enrollment growth slows or its economics disappoint; or partner/regulatory developments threaten service revenue. No valuation or price-level trigger is supplied, so avoid a price-target trade.